Welcome to the splice age: antisense oligonucleotide–mediated exon skipping gains wider applicability

Elizabeth M. McNally, Eugene J. Wyatt

*J Clin Invest.* 2016;126(4):1236-1238. [https://doi.org/10.1172/JCI86799](https://doi.org/10.1172/JCI86799).

**Commentary**

Exon skipping uses antisense oligonucleotides (ASOs) to alter transcript splicing for the purpose of rescuing or modulating protein expression. In this issue of the *JCI*, Lee and colleagues developed and evaluated an ASO-dependent method for treating certain molecularly defined diseases associated with alterations in lamin A/C (*LMNA*) splicing. Exon skipping by ASOs is gaining traction as a therapeutic strategy, and the use of ASOs is now being applied to bypass mutations and generate modified but functional proteins for an array of genetic disorders.

Find the latest version:

[http://jci.me/86799-pdf](http://jci.me/86799-pdf)
Welcome to the splice age: antisense oligonucleotide–mediated exon skipping gains wider applicability

Elizabeth M. McNally and Eugene J. Wyatt
Center for Genetic Medicine, Northwestern University, Chicago, Illinois, USA.

Exon skipping uses antisense oligonucleotides (ASOs) to alter transcript splicing for the purpose of rescuing or modulating protein expression. In this issue of the *JCI*, Lee and colleagues developed and evaluated an ASO-dependent method for treating certain molecularly defined diseases associated with alterations in lamin A/C (LMNA) splicing. Exon skipping by ASOs is gaining traction as a therapeutic strategy, and the use of ASOs is now being applied to bypass mutations and generate modified but functional proteins for an array of genetic disorders.

Exon skipping and neuromuscular disease

There has been considerable progress toward using exon skipping for therapeutic intent for inherited muscle diseases in humans. Significant efforts have focused on such strategies for treating Duchenne muscular dystrophy (DMD), a lethal X-linked recessive disorder caused by mutations in the gene encoding dystrophin (reviewed in ref. 1). In the case of DMD, exon skipping is applied to convert out-of-frame mutations that ablate protein expression to those mutations that restore the open reading frame, thereby converting severe disease to milder disease. A primary antisense oligonucleotide (ASO) strategy in clinical development targets exon 51 of the dystrophin gene, as exon deletions proximal to this region are a relatively common cause of DMD. In the setting of these specific exon deletions, ASO-mediated exclusion of exon 51 generates in-frame mature RNA transcripts and rescues protein expression. The protein encoded by the ASO-modified transcript results in a relatively small internal deletion of the dystrophin protein (2).

Moving ASOs beyond DMD

With progress, ASO exon skipping approaches are now moving beyond the original DMD paradigm. Strategies for exon skipping have been developed for a number of neuromuscular conditions, including limb girdle muscular dystrophy (3), Pompe disease (4), cardiomyopathies (5, 6), and cystic fibrosis (7). Other approaches toward treating laminopathies have also been tested (8). For DMD, approaches extend beyond correction of the dystrophin gene and include combining ASO exon skipping with targeted reduction of myostatin (9, 10). ASO-induced exon skipping may be useful beyond rare genetic diseases, extending to disorders like rheumatoid arthritis (11) and cancer (12).

A strategy to treat laminopathies

In this issue, Lee and colleagues piloted an ASO-directed approach to treat Hutchinson Gilford progeria syndrome (HGPS) (13), a rare disorder that is often associated with a de novo dominant mutation in the lamin A/C (LMNA) gene that disrupts the processing of lamin A (14). Lamin A and lamin C are produced from a single gene through alternative splicing and together form the core filamentous structure that lines the inner nuclear membrane (Figure 1). Lamin A is initially produced as prelamin A, which includes an additional 98 amino acids at the carboxy terminus. Embedded in the last four amino acids of prelamin A are signals that direct farnesylation, which is linked to cleavage and processing to help localize mature lamin A at the inner nuclear membrane. Lamin C is encoded by an alternative splice form that terminates in exon 10 and does not undergo this maturation process. The de novo HGPS-causing mutation (c.1824 C>T) disrupts splicing and leads to excess accumulation of prelamin A, also called progerin.

Lee et al. designed and tested ASOs to shift the balance of splicing to encode less lamin A and more lamin C (13). The rationale for this shift was justified by previous observations in lamin C–only mice, which, by genetic design, do not express lamin A in favor of lamin C (15). Despite the loss of lamin A, lamin C–only mice have no discernible phenotype, suggesting that changing the lamin A/C ratio toward lamin C could be an effective strategy to treat HGPS and other LMNA-related diseases. Mutations in LMNA produce a wide array of genetic diseases. The most common LMNA mutant phenotypes induce myopathic processes that affect the heart and skeletal muscle (16); however, LMNA mutations also cause lipodystrophy-related phenotypes, bony malformation syndromes, and the premature aging phenotype seen in HGPS (16). Notably, the majority of LMNA mutant–related phenotypes are dominant; therefore, any ASO-targeted approach must specifically target the mutant allele and not the WT allele. Given that most mutations in LMNA are single nucleotide changes, it has proven challenging to design ASOs that preferentially target the mutant alleles. In such cases, off-target effects that affect the normal allele could result in knockdown of the entire gene product, leading

Related Article: p. 1592

Conflict of interest: E.M. McNally and E.J. Wyatt are coinventors on a patent related to exon skipping for limb girdle muscular dystrophy.

Figure 1. A schematic of the LMNA gene, which spans approximately 25 kbp on chromosome 1 and encodes lamin A and lamin C. (A) Lamin A and lamin C are produced from a single gene through alternative splicing. (B) Laminopathies result from mutations that alter lamin A processing. ASOs were designed to target exon 11 to shift the ratio of lamin A-encoding mRNA to lamin C-encoding mRNA. This strategy would treat laminopathies due to mutations in exon 11 and 12. Exons 1-12 are shown.

The splice age

As we move into the era of precise molecular correction, there are considerable limitations in moving these therapies into humans (21). In many instances, ASO-mediated exon skipping is only able to target subgroups of individuals with rare diseases, often requiring precise sequences designed to treat personalized diseases. Current regulatory procedures are not well suited to evaluate this type of rare disease treatment, and the path forward may require modification of the regulatory process. Treatment with ASOs is also expected to require lifelong administration and be costly, another significant barrier to implementing ASO exon skipping as a treatment for disease. As we look to the horizon, gene editing using CRISPR/Cas9 may develop based on similar principles to ASO-induced exon skipping and similarly may require precise treatment design for individual patients. Indeed, three recent studies have shown that such genome editing is able to at least partially restore dystrophin expression and improve skel-
ternal muscle function in dystrophic mice (22–24). While this offers tremendous promise as curative strategy for genetic disease, many hurdles exist before human clinical implementation. Thus, utilization of ASOs may prove to be an efficient bridge between current therapeutic options and the future of genetic medicine at the molecular, therapeutic, and regulatory levels. Welcome to the splice age.

Acknowledgments
This work was supported by NIH grant R01 HL061322.

Address correspondence to: Elizabeth M. McNally, 303 E. Superior St., Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. Phone: 312.503.5600; E-mail: Elizabeth.mcnelly@northwestern.edu.